TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.26
+1.17%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-15.9%
Return on equity
-15.5%
Return on assets
-18.5%
Return on invested capital
0.00x
Asset turnover
-$52.6M
Cash from operations
$2.24
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026